Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 126 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glomerular Disease Clear all
Not listed Phase 2 Interventional

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

NCT04939116
View directory record Official record
Conditions
Glomerular Disease, Proteinuria
Interventions
ANG-3070, Placebo
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Birmingham, Alabama • Northridge, California • Vacaville, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial

NCT00974636
View directory record Official record
Conditions
Kidney Disease
Interventions
Low Salt Diet, Usual Salt Diet
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

NCT05834738
View directory record Official record
Conditions
IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 5:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bariatric Surgery and the Kidney

NCT01410994
View directory record Official record
Conditions
Proteinuria
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

NCT02772276
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
MB-102-- single dose of 4 µmol/kg, MB-102-- single dose of 130 mg, MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart, MB-102-- two doses of 130 mg 24 hours apart, Iohexol, QuantumLeap, Radiance, Brilliance (1 or 2 sensors), Brilliance (2-part sensor)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Edgewater, Florida • Orlando, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Jul 22, 2026, 5:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Zigakibart in Adults With IgA Nephropathy

NCT05852938
View directory record Official record
Conditions
IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions
BION-1301, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Birmingham, Alabama • Huntsville, Alabama • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

NCT04950114
View directory record Official record
Conditions
Kidney Diseases, Glomerulosclerosis, Focal Segmental Nephrosis, Lipoid Urologic Disease, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Northridge, California • Victorville, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jul 22, 2026, 5:19 AM EDT
Recruiting No phase listed Observational

Home Reported Outcomes in C3G Study

NCT07029542
View directory record Official record
Conditions
C3 Glomerulopathy
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

NCT00446459
View directory record Official record
Conditions
Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
Interventions
mycophenolate mofetil (CellCept)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

NCT02795676
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 (pegunigalsidase alfa), agalsidase beta
Biological
Lead sponsor
Protalix
Industry
Eligibility
18 Years to 60 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jul 22, 2026, 5:19 AM EDT
Completed No phase listed Observational

Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data

NCT03605810
View directory record Official record
Conditions
Renal Function
Interventions
No Intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5,132,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

NCT02017171
View directory record Official record
Conditions
Diabetic Nephropathies, Coronary Artery Disease
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Not applicable Interventional Results available

Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease

NCT01684722
View directory record Official record
Conditions
Diabetes
Interventions
Vitamin D, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jul 22, 2026, 5:19 AM EDT
Enrolling by invitation Not applicable Interventional

Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

NCT05514184
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
Interventions
PLAFOND diet
Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Orange, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Results available

A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

NCT01484561
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550 or Placebo, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
South Miami, Florida • Albany, New York • Duncansville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Jul 22, 2026, 5:19 AM EDT
Recruiting Phase 3 Interventional

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618
View directory record Official record
Conditions
C3G
Interventions
Placebo, iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Aurora, Colorado • Miami, Florida • Lawrenceville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 5:19 AM EDT
Terminated Not applicable Interventional Results available

Effect of Moderate Caloric Restriction on Glomerular Growth After Kidney Transplantation

NCT03607500
View directory record Official record
Conditions
Kidney Transplant; Complications, Glomerular Disease, Weight Gain, Kidney Transplant
Interventions
caloric intake reduction
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 22, 2026, 5:19 AM EDT
Withdrawn Phase 1 Interventional

TP10 Use in Patients With C3 Glomerulopathy (C3G)

NCT02302755
View directory record Official record
Conditions
Dense Deposit Disease
Interventions
TP10
Drug
Lead sponsor
University of Iowa
Other
Eligibility
4 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 22, 2026, 5:19 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy

NCT04080076
View directory record Official record
Conditions
Renal Disease
Interventions
Acthar 80 UNT/ML Injectable Solution, Oral Tab Tacrolimus
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
65 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lawrenceville, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Obesity and Protein Intake on the Kidney

NCT00244790
View directory record Official record
Conditions
Kidney Diseases
Interventions
Diet
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Feasibility Study of Metformin Therapy in ADPKD

NCT02903511
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jul 22, 2026, 5:19 AM EDT
Withdrawn Not applicable Interventional

Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease

NCT01426724
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Contrast Enhanced Ultrasonography
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of MP-3180 in Healthy Volunteers

NCT02098174
View directory record Official record
Conditions
Glomerular Filtration Rate, Acute Kidney Injury
Interventions
MP-3180, Iohexol comparator
Drug · Other
Lead sponsor
MediBeacon
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Jul 22, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)

NCT02521181
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lower Dose Sodium Bicarbonate, Higher Dose Sodium Bicarbonate, Placebo
Drug
Lead sponsor
Jennifer Gassman, PhD
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jul 22, 2026, 5:19 AM EDT